AC
SNDX icon

Athanor Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Athanor Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-21,621
Closed -$481K – 1021
2020
Q4 		$481K Buy
21,621
+3,260
+18% +$67.6K 0.01% 477
2020
Q3 		$271K Sell
18,361
-3,579
-16% -$54.6K 0.01% 446
2020
Q2 		$325K Buy
+21,940
New +$334K 0.02% 391
2019
Q3 		– Sell
-11,200
Closed -$104K – 227
2019
Q2 		$104K Buy
+11,200
New +$81.6K 0.01% 139

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Athanor Capital's SNDX Position: Q1 2021 in Review

Athanor Capital sold out of Syndax Pharmaceuticals (SNDX) in Q1 2021, closing a stake of 21,621 shares — an estimated $481K sold.

Athanor Capital first reported a position in SNDX in Q2 2019 and held it in 4 quarters. The position peaked at $481K in Q4 2020. 130 funds tracked by Wall St. Rank hold SNDX as of Q1 2021.

  • Athanor Capital reported no remaining Syndax Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 21,621 Syndax Pharmaceuticals shares in Q1 2021, an estimated $481K.
  • Athanor Capital first reported a position in Syndax Pharmaceuticals in Q2 2019 and held it in 4 quarters.
  • Athanor Capital's Syndax Pharmaceuticals position peaked at $481K in Q4 2020.
  • 130 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.